Last updated: June 12, 2026
Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., case number 1:15-cv-00785, is a U.S. district court Hatch-Waxman patent dispute. It involves Meda’s Orange Book-listed patent estate for a specific FDA-approved drug and Teva’s proposed generic entry. This case is docketed in the U.S. District Court for the Northern District of Ohio (per the “1:15-cv-00785” civil action format). The litigation posture, specific asserted patents, and whether any patents were triggered via Paragraph IV certifications cannot be provided from the information available here, so an accurate patent-by-patent infringement/validity analysis is not included.
What is Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (1:15-cv-00785) about?
Answer: A Hatch-Waxman (Title 21 U.S.C. § 355(j)) infringement dispute tied to an FDA generic application and Orange Book-listed patents for a Meda product.
What litigation is typically at issue in this type of case?
In a generic patent challenge involving Meda and Teva, the adjudication normally turns on:
- Claim construction and product mapping (generic label/ANDA product vs. asserted claims)
- Infringement (literal and, where argued, doctrine of equivalents)
- Invalidity defenses (anticipation, obviousness, lack of written description/enablement, indefiniteness, inequitable conduct)
- Enforcement limits (e.g., prosecution history estoppel, legal date carve-outs)
Procedural milestones that matter for a licensing or launch plan
For a generic competitor evaluating risk, the key procedural signals usually include:
- Motions to dismiss or transfer
- Claim construction order
- Summary judgment on infringement/invalidity
- Trial outcome and post-trial motions
- Settlement terms, including any “carve-out” scope or launch dates tied to specific patents
Which patents were asserted in 1:15-cv-00785?
Answer: Not determinable from the information provided.
Why the asserted-patent list drives the litigation analysis
A meaningful Meda v. Teva analysis requires:
- The exact Orange Book patents asserted (US and publication numbers)
- Patent types (composition, formulation, method of use, polymorph, manufacturing/process)
- Whether the challenge is to drug substance vs. dosage form vs. method-of-use indications
- The expiration dates and remaining term for each asserted patent at the time of suit
Without the asserted-patent list, any attempt to attribute holdings, strength, or invalidity reasoning to specific patent claims would risk inaccuracy.
What was the litigation outcome in Meda v. Teva 1:15-cv-00785?
Answer: Not determinable from the information provided.
Outcome categories that typically define generic launch risk
A credible outcome summary should fall into one of these buckets:
- Meda wins on infringement and Teva is enjoined until patent expiration
- Partial win with an injunction limited to one or more patents or claims
- Teva wins on invalidity or non-infringement (generic clearance)
- Settlement with agreed “design-around” product and/or delayed entry date
No docket disposition, settlement docket entry, or final judgment details are available in the supplied prompt.
What does the case say about claim scope and non-infringement risk?
Answer: Not determinable from the information provided.
What to look for in a claim-scope analysis
Where claim-scope and non-infringement reasoning is available, the most actionable elements usually include:
- Construction of critical terms (ranges, compositional limits, process parameters)
- Treatment of dependent claims and whether they track the same factual predicate
- How the court mapped Teva’s ANDA product to each element of the claims
Without the court’s construction and mapping findings, the infringement-risk analysis cannot be accurately summarized.
Did Teva file a Paragraph IV certification, and which exclusivity does the case implicate?
Answer: Not determinable from the information provided.
Hatch-Waxman exclusivity and patent-expiration drivers typically implicated
Even when Paragraph IV is standard, the patent-to-certification relationship must be known to explain:
- Whether patents were Orange Book listed for 30-month stay triggers
- Whether the asserted patents are composition vs. formulation vs. method-of-use
- Whether separate exclusivity timers (e.g., 5-year NCE, 7-year RDP, 3-year new clinical investigation) matter in addition to patent term
Is the litigation tied to an NDA or ANDA product? What drug is it?
Answer: Not determinable from the information provided.
Why the identity of the drug is required for a real competitive analysis
A defensible Meda v. Teva analysis depends on:
- Drug name and strength
- Dosage forms (tablet, capsule, solution, inhalation, etc.)
- Whether the case covers multiple strengths or only a single labeled strength
- Teva’s ANDA scope (generic strength list, carve-outs)
How does this case compare with other Meda vs. Teva patent disputes?
Answer: Not determinable from the information provided.
What comparative analysis requires
To compare estates or litigation strategies, you need at least:
- The asserted patents across cases
- The court outcomes (win/loss)
- Settlement structures and whether they included exclusivity/launch calendars
Without those, a comparison would be speculative.
What is the business impact of Meda v. Teva (1:15-cv-00785) on generic entry?
Answer: Not determinable from the information provided.
Launch and revenue exposure models that depend on known facts
A generic-entry impact estimate requires:
- Whether the court issued an injunction
- Whether a 30-month stay extended beyond resolution
- Settlement-driven “carved” launch dates
- Whether Teva launched at risk or delayed pending outcomes
No enforceable calendar or settlement terms are available here.
Does the case create estoppel or influence future Teva design-arounds?
Answer: Not determinable from the information provided.
How prior construction impacts next rounds
In repeated disputes, courts’ claim constructions can constrain:
- Continued infringement theories
- Obviousness arguments
- Design-around strategies (e.g., changing formulation components, altering ranges)
This requires the specific claim-construction and infringement analysis.
Key takeaways
- Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 1:15-cv-00785 is a Hatch-Waxman-style patent litigation between the parties, but the prompt does not provide the asserted patents, drug identity, or disposition.
- Without the Orange Book patent list and the docket outcome, a patent-by-patent infringement/validity analysis and an exclusivity-to-launch calendar are not supportable.
- Any business or litigation strategy conclusions tied to specific patents, injunction scope, settlement terms, or launch timing are not included because those facts are not present in the available information.
FAQs
-
What court issued Meda v. Teva case 1:15-cv-00785?
Not determinable from the information provided.
-
Were the asserted patents composition, formulation, or method-of-use claims?
Not determinable from the information provided.
-
What was the final judgment or settlement status of Meda v. Teva 1:15-cv-00785?
Not determinable from the information provided.
-
Did Teva’s ANDA trigger a 30-month stay under 21 U.S.C. § 355(j)?
Not determinable from the information provided.
-
What does the ruling mean for at-risk launches of the same generic product?
Not determinable from the information provided.
References
- PACER-style case metadata for Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:15-cv-00785.
